Kamel LARIBI

Dr. Kamel LARIBI


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 October 2020 in Blood Advances
Verified
Journal Article
Open access
PDF file
KLKamel LARIBI
Kamel LARIBI
AMAlix Baugier de Materre
Alix Baugier de Materre
MSMohamad Sobh
Mohamad Sobh
LCLorenzo Cerroni
Lorenzo Cerroni
CVCaterina Giovanna Valentini
Caterina Giovanna Valentini
TPTony Petrella
Tony Petrella
The purpose of this study is to describe the clinical and prognostic features and to evaluate the outcome of different therapeutic approaches among patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) who have been diagnosed and treated in different institutions. A total of 398 patients from 75 centers were included in the study. Treatment consisted of non-Hodgkin lymphoma (NHL)–like regimens in 129 (32.8%) patients and acute leukemia (AL)–like regimens in 113 (23.5%) patients. In 61 (15.5%) and 16 (4.1%) patients, chemotherapy was followed by allogeneic and autologous hematopoietic stem cell transplantation (HSCT), respectively. Twenty-seven (6.9%) patients received radiotherapy, 6 (1.5%) received new agents, and 62 (15.7%) received palliative care. After a median follow-up of 12 months, median overall survival (OS) was 18 months. Patients who received NHL/AL-like regimens, followed by allogeneic HSCT, had the best outcome; median OS was not reached. OS was 65 months for patients who underwent autologous HSCT; 18 months and 14 months, respectively, for those treated with AL-like and NHL-like regimens without consolidation; and 4 months for those receiving palliative care (P < .001). In BPDCN, chemotherapy with lymphoma- or AL-like regimens, followed by transplantation, represents the therapeutic strategy associated with the best outcome. Consolidation with allogeneic HSCT, when feasible, appears superior to autologous HSCT.

12 December 2018 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
KLKamel LARIBI
Kamel LARIBI
SPStéphanie Poulain
Stéphanie Poulain
LWLise Willems
Lise Willems
FMFatiha Merabet
Fatiha Merabet
RCRonan Le Calloch
Ronan Le Calloch
VLVéronique Leblond
Véronique Leblond

27 February 2014 in European Journal of Haematology
Verified
Journal Article
Closed access
PDF file
KLKamel LARIBI
Kamel LARIBI
NDNathalie Denizon
Nathalie Denizon
HGHabib Ghnaya
Habib Ghnaya
MAMustapha Atlassi
Mustapha Atlassi
ABAnne Besançon
Anne Besançon
TPTony Petrella
Tony Petrella

19 April 2018 in The Oncologist
Verified
Journal Article
Closed access
PDF file
KLKamel LARIBI
Kamel LARIBI
MAMustapha Alani
Mustapha Alani
CTCatherine Truong
Catherine Truong
AMAlix Baugier de Materre
Alix Baugier de Materre
Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of clinically aggressive diseases associated with poor outcome. Despite progress in the last several years, resulting in a deeper understanding of the natural history and biology of PTCL based on molecular profiling and next-generation sequencing, there is a need for improvement in efficacy of chemotherapeutic regimens for newly diagnosed patients. Treatment in the front-line setting is most often cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP-like regimens, which are associated with a high failure rate and frequent relapses. Trials evaluating intensive chemotherapy have resulted in variable success in prolonging event-free survival, but overall survival has remained unchanged. Furthermore, this strategy is limited to patients who are in complete remission after initial anthracycline-based chemotherapy. Many patients are ineligible for hematopoietic stem cell transplantation because of age or failure to achieve remission. For relapsed disease, advances have been made in the therapeutic arsenal for PTCL. New drugs investigated in phase II studies have achieved response rates between 10% and 30%. However, to date the identification of new therapies has been largely empiric, and long-term remissions are the exception to the rule. Current patient outcomes suggest the need for the identification and development of active and biologically rational therapies to improve disease management and to extend the duration of response with iterative biomarker evaluation. This review covers the management of PTCL and focuses on new agents and therapeutic combinations, based on a better understanding of biology and pathogenesis of the disease. Implications for Practice: Recent progress in understanding of the biology and pathogenesis of peripheral T-cell lymphoma has led to the emergence of new drugs. Unfortunately, this has not been met with similar advances in outcome improvement. Anthracycline-containing regimens, mostly cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), are considered the standard of care, although the best first-line approach remains to be defined. In the relapsed and refractory settings, several new agents achieved response rates between 10% and 30%, although these drugs do not significantly affect survival rates. Therapeutic options based on better molecular characterization of various histological types and combinations with the CHOP regimen or synergic combinations of new drugs may lead to better outcomes.

1 August 2016 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
KLKamel LARIBI
Kamel LARIBI
NDNathalie Denizon
Nathalie Denizon
ABAnne Besançon
Anne Besançon
JFJonathan Farhi
Jonathan Farhi
PLPierre Lemaire
Pierre Lemaire
AMAlix Baugier de Materre
Alix Baugier de Materre
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematological malignancy with an aggressive clinical course. It is grouped with acute myeloid leukemia-related precursor neoplasms in the 2008 World Health Organization classification. Most patients with BPDCN have skin lesions at diagnosis and subsequent or simultaneous involvement of the bone marrow, peripheral blood, and lymph nodes. Patients usually respond to initial chemotherapy but often relapse. Stem cell transplantation may improve survival. This neoplasm is derived from precursors of plasmacytoid dendritic cells and is characterized by the coexpression of the immunophenotypic markers CD4, CD56, CD123, blood dendritic cell antigen-2, blood dendritic cell antigen-4, CD2AP, and lineage(-). Atypical immunophenotype expression may be present, making diagnosis difficult. BPDCN is often associated with a complex karyotype, frequent deletions of tumor suppressor genes, and mutations affecting either the DNA methylation or chromatin remodeling pathways. A better understanding of the etiology and pathophysiology of this neoplasm could open the way to new therapies targeting specific signaling pathways or involving epigenetics.

3 August 2016 in Annals of Hematology
Verified
Journal Article
Closed access
PDF file
KLKamel LARIBI
Kamel LARIBI
NDNathalie Denizon
Nathalie Denizon
DBDelphine Bolle
Delphine Bolle
CTCatherine Truong
Catherine Truong
ABAnne Besançon
Anne Besançon
AMAlix Baugier de Materre
Alix Baugier de Materre